cyc 202 has been researched along with HIV Coinfection in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, V; Das, P; Purohit, R; Singh, R | 1 |
| Choi, BS; Kang, C; Kim, K; Kim, KC; Shin, Y; Yoon, CH | 1 |
| De Clercq, E; Liu, XY; Wang, Y | 1 |
| Doniger, J; Mayner, R; Sadaie, MR | 1 |
| Fischer, PM; Gianella-Borradori, A | 1 |
| Berro, R; Chao, SH; de la Fuente, C; Kashanchi, F; Nekhai, S; Pumfery, A | 1 |
| de la Fuente, C; Deng, L; Denny, T; Eadie, C; Harrison, LE; Healey, M; Kashanchi, F; Meijer, L; Stein, D; Wang, D; Wang, L; Zilberman, I | 1 |
| Gelman, IH; Klotman, PE; Nelson, PJ | 1 |
4 review(s) available for cyc 202 and HIV Coinfection
| Article | Year |
|---|---|
Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof.
Topics: Flavonoids; HIV Infections; HIV-1; Humans; Models, Biological; Piperidines; Positive Transcriptional Elongation Factor B; Protein Kinase Inhibitors; Purines; RNA, Small Nuclear; Roscovitine; Transcription, Genetic | 2009 |
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Camptothecin; Cyclin-Dependent Kinases; Flavonoids; HIV; HIV Infections; Humans; Piperidines; Purines; Receptors, Estrogen; Roscovitine; Topoisomerase I Inhibitors; Virus Replication | 2004 |
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Flavonoids; Glomerulonephritis; Hematologic Neoplasms; HIV Infections; Humans; Molecular Sequence Data; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic | 2005 |
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
Topics: Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Flavonoids; Gene Expression Regulation, Viral; HIV Infections; Humans; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Virus Replication | 2006 |
4 other study(ies) available for cyc 202 and HIV Coinfection
| Article | Year |
|---|---|
Natural analogues inhibiting selective cyclin-dependent kinase protein isoforms: a computational perspective.
Topics: Cyclin-Dependent Kinase 2; HIV Infections; Humans; Ligands; Molecular Docking Simulation; Protein Isoforms; Protein Kinase Inhibitors; Roscovitine | 2020 |
Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects.
Topics: Anti-HIV Agents; Doxycycline; Drug Evaluation, Preclinical; Gene Expression Regulation, Viral; HeLa Cells; HIV Infections; HIV-1; Humans; Luciferases; Purines; RNA, Viral; Roscovitine; Sensitivity and Specificity; tat Gene Products, Human Immunodeficiency Virus; Transcription, Genetic | 2017 |
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
Topics: Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Peptides; Purines; Roscovitine; Virus Replication | 2001 |
Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes.
Topics: Animals; Apoptosis; Cell Differentiation; Cells, Cultured; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Genes, Viral; HIV Infections; HIV-1; Kidney; Mice; Piperidines; Purines; Roscovitine; Transcription, Genetic | 2001 |